Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $395.25 | 18 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $239.93 | 13 | $0 (2024) |
| Lilly USA, LLC | $92.74 | 1 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $62.58 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $40.26 | 2 | AstraZeneca Pharmaceuticals LP ($40.26) |
| 2023 | $81.31 | 4 | AstraZeneca Pharmaceuticals LP ($62.93) |
| 2022 | $52.28 | 3 | AstraZeneca Pharmaceuticals LP ($52.28) |
| 2021 | $17.12 | 1 | AstraZeneca Pharmaceuticals LP ($17.12) |
| 2020 | $17.83 | 1 | AstraZeneca Pharmaceuticals LP ($17.83) |
| 2019 | $143.66 | 4 | Lilly USA, LLC ($92.74) |
| 2017 | $42.79 | 3 | AstraZeneca Pharmaceuticals LP ($30.56) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.62 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/18/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $20.64 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/25/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/25/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $23.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/04/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | SYNJARDY (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: DIABETES | ||||||
| 02/07/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.11 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/04/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/06/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/19/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/08/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.12 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/22/2020 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/03/2019 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $92.74 | General |
| Category: Diabetes | ||||||
| 09/09/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: DIABETES | ||||||
| 07/15/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | TRADJENTA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: DIABETES | ||||||
| 06/20/2019 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.95 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/12/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug), TRADJENTA | Food and Beverage | In-kind items and services | $12.23 | General |
| Category: DIABETES | ||||||
| 05/09/2017 | AstraZeneca Pharmaceuticals LP | BEVESPI AEROSPHERE (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Respiratory | ||||||
| 03/09/2017 | AstraZeneca Pharmaceuticals LP | BYDUREON (Drug) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 15 | 38 | $2,871 | $1,800 |
| 2022 | 1 | 17 | 65 | $4,911 | $2,612 |
| 2021 | 2 | 36 | 104 | $6,461 | $3,118 |
| 2020 | 2 | 40 | 121 | $7,382 | $4,203 |
All Medicare Procedures & Services
6 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 38 | $2,871 | $1,800 | 62.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 65 | $4,911 | $2,612 | 53.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 23 | 81 | $6,120 | $2,999 | 49.0% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2021 | 13 | 23 | $341.09 | $119.02 | 34.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 26 | 92 | $6,952 | $3,958 | 56.9% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2020 | 14 | 29 | $430.07 | $245.05 | 57.0% |
About Dr. Yaralin Planell, M.D
Dr. Yaralin Planell, M.D is a General Practice healthcare provider based in Lares, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770681314.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Yaralin Planell, M.D has received a total of $395.25 in payments from pharmaceutical and medical device companies, with $40.26 received in 2024. These payments were reported across 18 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($395.25).
As a Medicare-enrolled provider, Planell has provided services to 108 Medicare beneficiaries, totaling 328 services with total Medicare billing of $11,732. Data is available for 4 years (2020–2023), covering 6 distinct procedure/service records.
Practice Information
- Specialty General Practice
- Location Lares, PR
- Active Since 09/20/2006
- Last Updated 12/04/2014
- Taxonomy Code 208D00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1770681314
Products in Payments
- FARXIGA (Drug) $209.37
- JARDIANCE (Drug) $104.97
- TRADJENTA (Drug) $31.97
- SYNJARDY (Drug) $18.38
- BYDUREON (Drug) $15.93
- BEVESPI AEROSPHERE (Drug) $14.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
General Practice Doctors in Lares
Dr. Waleska Gonzalez Nieves, M.d, M.D
General Practice — Payments: $3,778
Dr. Jorge Ballester Echegaray, M.d, M.D
General Practice — Payments: $1,479
Geraldo Gonzalez, M.d, M.D
General Practice — Payments: $716.43
Mr. Jose Lopez-Lopez, Dds, DDS
General Practice — Payments: $684.77
Dr. Carlos Planell Dosal, M.d, M.D
General Practice — Payments: $554.60
Dr. Juan Chaparro, M.d, M.D
General Practice — Payments: $507.35